




UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov



NOTICE OF ALLOWANCE AND FEE(S) DUE

26111 7590 03/13/2003

STERNE, KESSLER, GOLDSTEIN & FOX PLLC
1100 NEW YORK AVENUE, N.W., SUITE 600
WASHINGTON, DC 20005-3934

STERNE, KESSLER, GOLDSTEIN & FOX PLLC EXAMINER	
ART UNIT	CLASS-SUBCLASS

1626

514-407000

DATE MAILED: 03/13/2003

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/814,123	03/22/2001	Derk J. Hogenkamp	1861.1270001/JMC/THN	2060

TITLE OF INVENTION: ARYL SUBSTITUTED PYRAZOLES, TRIAZOLES, AND TETRAZOLES, AND THE USE THEREOF

APPLN. TYPE	SMALL ENTITY	ISSUE FEE	PUBLICATION FEE	TOTAL FEE(S) DUE	DATE DUE
nonprovisional	NO	\$1300	\$300	\$1600	06/13/2003

THE APPLICATION IDENTIFIED ABOVE HAS BEEN EXAMINED AND IS ALLOWED FOR ISSUANCE AS A PATENT. PROSECUTION ON THE MERITS IS CLOSED. THIS NOTICE OF ALLOWANCE IS NOT A GRANT OF PATENT RIGHTS. THIS APPLICATION IS SUBJECT TO WITHDRAWAL FROM ISSUE AT THE INITIATIVE OF THE OFFICE OR UPON PETITION BY THE APPLICANT. SEE 37 CFR 1.313 AND MPEP 1308.

THE ISSUE FEE AND PUBLICATION FEE (IF REQUIRED) MUST BE PAID WITHIN THREE MONTHS FROM THE MAILING DATE OF THIS NOTICE OR THIS APPLICATION SHALL BE REGARDED AS ABANDONED. THIS STATUTORY PERIOD CANNOT BE EXTENDED. SEE 35 U.S.C. 151. THE ISSUE FEE DUE INDICATED ABOVE REFLECTS A CREDIT FOR ANY PREVIOUSLY PAID ISSUE FEE APPLIED IN THIS APPLICATION. THE PTOL-85B (OR AN EQUIVALENT) MUST BE RETURNED WITHIN THIS PERIOD EVEN IF NO FEE IS DUE OR THE APPLICATION WILL BE REGARDED AS ABANDONED.

HOW TO REPLY TO THIS NOTICE:

I. Review the SMALL ENTITY status shown above.

If the SMALL ENTITY is shown as YES, verify your current SMALL ENTITY status:

A. If the status is the same, pay the TOTAL FEE(S) DUE shown above.

B. If the status is changed, pay the PUBLICATION FEE (if required) and twice the amount of the ISSUE FEE shown above and notify the United States Patent and Trademark Office of the change in status, or

If the SMALL ENTITY is shown as NO:

A. Pay TOTAL FEE(S) DUE shown above, or

B. If applicant claimed SMALL ENTITY status before, or is now claiming SMALL ENTITY status, check the box below and enclose the PUBLICATION FEE and 1/2 the ISSUE FEE shown above.

☐ Applicant claims SMALL ENTITY status.
See 37 CFR 1.27.

II. PART B - FEE(S) TRANSMITTAL should be completed and returned to the United States Patent and Trademark Office (USPTO) with your ISSUE FEE and PUBLICATION FEE (if required). Even if the fee(s) have already been paid, Part B - Fee(s) Transmittal should be completed and returned. If you are charging the fee(s) to your deposit account, section "4b" of Part B - Fee(s) Transmittal should be completed and an extra copy of the form should be submitted.

III. All communications regarding this application must give the application number. Please direct all communications prior to issuance to Box ISSUE FEE unless advised to the contrary.

IMPORTANT REMINDER: Utility patents issuing on applications filed on or after Dec. 12, 1980 may require payment of maintenance fees. It is patentee's responsibility to ensure timely payment of maintenance fees when due.



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/814,123	03/22/2001	Derk J. Hogenkamp	1861.1270001/JMC/THN	2060
26111	7590	03/13/2003	EXAMINER	
STERNE, KESSLER, GOLDSTEIN & FOX PLLC 1100 NEW YORK AVENUE, N.W., SUITE 600 WASHINGTON, DC 20005-3934			SHAMEEM, GOLAM M	
			ART UNIT	PAPER NUMBER

1626

DATE MAILED: 03/13/2003

Determination of Patent Term Adjustment under 35 U.S.C. 154 (b)
(application filed on or after May 29, 2000)

The patent term adjustment to date is 0 days. If the issue fee is paid on the date that is three months after the mailing date of this notice and the patent issues on the Tuesday before the date that is 28 weeks (six and a half months) after the mailing date of this notice, the term adjustment will be 0 days.

If a continued prosecution application (CPA) was filed in the above-identified application, the filing date that determines patent term adjustment is the filing date of the most recent CPA.

Applicant will be able to obtain more detailed information by accessing the Patent Application Information Retrieval (PAIR) system. (<http://pair.uspto.gov>)

Any questions regarding the patent term extension or adjustment determination should be directed to the Office of Patent Legal Administration at (703)305-1383.



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/814,123	03/22/2001	Derk J. Hogenkamp	1861.1270001/JMC/THN	2060
26111	7590	03/13/2003	EXAMINER	
STERNE, KESSLER, GOLDSTEIN & FOX PLLC 1100 NEW YORK AVENUE, N.W., SUITE 600 WASHINGTON, DC 20005-3934 UNITED STATES			SHAMEEM, GOLAM M	
			ART UNIT	PAPER NUMBER
			1626	

DATE MAILED: 03/13/2003

Notice of Fee Increase on January 1, 2003

If a reply to a "Notice of Allowance and Fee(s) Due" is filed in the Office on or after January 1, 2003, then the amount due will be higher than that set forth in the "Notice of Allowance and Fee(s) Due" since there will be an increase in fees effective on January 1, 2003. See Revision of Patent and Trademark Fees for Fiscal Year 2003; Final Rule, 67 Fed. Reg. 70847, 70849 (November 27, 2002).

The current fee schedule is accessible from: <http://www.uspto.gov/main/howtofees.htm>.

If the issue fee paid is the amount shown on the "Notice of Allowance and Fee(s) Due," but not the correct amount in view of the fee increase, a "Notice to Pay Balance of Issue Fee" will be mailed to applicant. In order to avoid processing delays associated with mailing of a "Notice to Pay Balance of Issue Fee," if the response to the Notice of Allowance and Fee(s) due form is to be filed on or after January 1, 2003 (or mailed with a certificate of mailing on or after January 1, 2003), the issue fee paid should be the fee that is required at the time the fee is paid. If the issue fee was previously paid, and the response to the "Notice of Allowance and Fee(s) Due" includes a request to apply a previously-paid issue fee to the issue fee now due, then the difference between the issue fee amount at the time the response is filed and the previously paid issue fee should be paid. See Manual of Patent Examining Procedure, Section 1308.01 (Eighth Edition, August 2001).

Questions relating to issue and publication fee payments should be directed to the Customer Service Center of the Office of Patent Publication at (703) 305-8283.

Notice of Allowability

Application No.

09/814,123

Examiner

Golam M M Shameem

Applicant(s)

HOGENKAMP ET AL.

Art Unit

1626

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address--

All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. **THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS.** This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.

1. ☒ This communication is responsive to 2/14/03.
2. ☒ The allowed claim(s) is/are 1-10, 15-17, 22-25 and 28-31 (renumbered 1-21).
3. ☐ The drawings filed on _____ are accepted by the Examiner.
4. ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
 - a) ☐ All b) ☐ Some* c) ☐ None of the:
 1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).
 - * Certified copies not received: _____.
5. ☒ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).
 - (a) ☐ The translation of the foreign language provisional application has been received.
6. ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application. **THIS THREE-MONTH PERIOD IS NOT EXTENDABLE**

7. ☐ A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.
8. ☐ CORRECTED DRAWINGS must be submitted.
 - (a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached
 - 1) ☐ hereto or 2) ☐ to Paper No. _____.
 - (b) ☐ including changes required by the proposed drawing correction filed _____, which has been approved by the Examiner.
 - (c) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No. _____.

Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the top margin (not the back) of each sheet. The drawings should be filed as a separate paper with a transmittal letter addressed to the Official Draftsperson.

9. ☐ DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.

Attachment(s)

- | | |
|---|---|
| 1 <input type="checkbox"/> Notice of References Cited (PTO-892) | 2 <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) |
| 3 <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | 4 <input type="checkbox"/> Interview Summary (PTO-413), Paper No. _____ |
| 5 <input checked="" type="checkbox"/> Information Disclosure Statements (PTO-1449), Paper No. <u>5, 8</u> . | 6 <input type="checkbox"/> Examiner's Amendment/Comment |
| 7 <input type="checkbox"/> Examiner's Comment Regarding Requirement for Deposit of Biological Material | 8 <input checked="" type="checkbox"/> Examiner's Statement of Reasons for Allowance |
| | 9 <input type="checkbox"/> Other |

DETAILED ACTION

Status of Claims

Claims 1-10, 15-17, 22-25 and 28-31 are pending in the application. Receipt is also acknowledged of amendment / response (paper No. 13) filed on February 14, 2003. Claims 3, 15, 16, 17, and 22 have been amended. Claims 28-31 have been added. Claims 11-14, 18-21, 26 and 27 have been canceled.

Reasons for allowance

The following is an Examiner's statement of reasons for allowance:

Betageri et al (WO 99/62855) teach the substituted aminophenyl pyrazoles and their use as anti-inflammatory agents. The instant compounds differ from the prior art by having the formula I, which is further substituted by different variables such as R¹, R², R³, R⁵, R⁶, R⁷, and R⁸ etc., which are attached directly, or indirectly to the core pyrazole (Het) structure that may be useful as therapeutic agents. The prior art compound neither teach nor render obvious the instant claimed invention and there is no suggestion or motivation to modify the compound of other prior art to obtain the instant compounds. Therefore the instant claims are allowable over the prior art of record.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Golam Shameem, Ph.D. whose telephone number is (703) 305-0116. The examiner can normally be reached on Monday-Thursday from 6:30 AM - 5:00 PM. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Joseph McKane, can be reached at (703) 308-4537. The Unofficial fax phone number for this

Art Unit: 1626


Group is (703) 308-7922. The Official fax phone numbers for this Group are (703) 308-4556 or 305-3592.

When filing a FAX in Technology Center 1600, please indicate in the Header (upper right) "Official" for papers that are to be entered into the file, and "Unofficial" for draft documents and other communications with the PTO that are not for entry into the file of the application. This will expedite processing of your papers.


Communications via Internet e-mail regarding this application, other than those under 35 U.S.C. 132 or which otherwise require a signature, may be used by the applicant and should be addressed to [joseph.mcKane@uspto.gov]. All Internet e-mail communications will be made of record in the application file. PTO employees will not communicate with applicant via Internet e-mail where sensitive data will be exchanged or where there exists a possibility that sensitive data could be identified unless there is of record an express waiver of the confidentiality requirements under 35 U.S.C. 122 by the applicant. See the Interim Internet Usage Policy published by the Patent and Trademark Office Official Gazette on February 25, 1997 at 1195 OG 89.

Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist, whose telephone number is (703) 308-1235.

Golam M M Shameem, Ph.D.
Patent Examiner
Art Unit 1626, Group 1620
Technology Center 1


Joseph K McKane
Supervisory Patent Examiner
Art Unit 1626, Group 1626
Technology Center 1

March 5, 2003



RECEIVED

DEC 26 2001

TECH CENTER 1600/2900

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTORNEY/POCKET NO. MARK OFFICE
1861.1274418/THNAPPLICATION NO.
09/814, 123APPLICANT
Hogenkamp et al.FILING DATE
March 22, 2001GROUP
1626

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
GS	AA2	6,057,346	05/02/2000	Kohn et al.	514	359	12/12/1994
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AR		
AS		
AT		


EXAMINER

Shameem

DATE CONSIDERED

1/30/03

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



RECEIVED

DEC 26 2001

TECH CENTER 1600/2000

1 of 2

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 1861.1270001/JMC/THN	APPLICATION NO. 09/814,123
	APPLICANT Hogenkamp <i>et al.</i>	
	FILING DATE March 22, 2001	GROUP 1626

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
GS	AJ1	5,602,156	02/11/1997	Kohn <i>et al.</i>	514	359	03/10/1994
GS	AK1	5,744,492	04/28/1998	Kohn <i>et al.</i>	514	359	03/10/1994

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)			
	AR		
	AS		
	AT		

EXAMINER <i>Shamam</i>	DATE CONSIDERED 1/30/03
---------------------------	----------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
1861.1270001/JMC/THNAPPLICATION NO.
09/814,123APPLICANT
Hogenkamp et al.FILING DATE
March 22, 2001GROUP
1626

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
GS	AA1	3,049,438	08/14/1962	Buell and Long	117	33.5	11/03/1958
	AB1	3,058,989	10/16/1962	Buell and Long	260	296	11/26/1957
	AC1	4,072,498	02/07/1978	Moon et al.	71	92	05/14/1976
	AD1	4,394,514	07/19/1983	Kruse, L.I.	548	508	06/29/1981
	AE1	4,454,337	06/12/1984	Kruse, L.I.	560	22	03/02/1983
	AF1	4,639,266	01/27/1987	Heubach et al.	71	92	09/09/1985
	AG1	4,962,011	10/09/1990	Aldag et al.	430	281	05/17/1988
GS	AH1	5,134,142	07/28/1992	Matsuo et al.	514	255	09/14/1990
	AI1	5,670,533	09/23/1997	Matsuo et al.	514	106	12/28/1995
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
*	AL1	DE 19 36 760	01/22/1970	Germany			Abstract Yes No
*	AM1	DE 29 10 330 A1	10/02/1980	Germany			Abstract Yes No
GS	AN1	GB 2 105 327 A	03/23/1983	Great Britain			Yes No
GS	AO1	EP 0 273 528 A1	07/06/1988	Europe			Yes No
GS	AP1	EP 0 323 841 A2	07/12/1989	Europe			Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

GS	AR	1	Arient, J. and Dvořák, J., "Triphenylmethane dyes. II. Introduction of the triazole group into the triphenylmethane skeleton," <i>Chem. Abstracts</i> 52:Abstract No. 124011, The American Chemical Society (1958).
	AS	1	Baud, J., et al., "CGP 31358 binds to a site on the NMDA receptor that is coupled to both the transmitter recognition site and the channel domain," <i>Neurosci. Lett.</i> 107:184-188, Elsevier Scientific Publishers Ireland Ltd. (1989).
GS	AT	1	Bensimon, G., et al., "A Controlled Trial of Riluzole in Amyotrophic Lateral Sclerosis," <i>New Eng. J. Med.</i> 330:585-591, Massachusetts Medical Society (1994).

EXAMINER

Ans hameem

DATE CONSIDERED

8/5/03

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

P:\USERS\JMYZKON\1861\1270001\PTO 1449

SEP Rev. 1/95

* Non-english documents

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT				ATTY. DOCKET NO. 1861.1270001/JMC/THM		APPLICATION NO. 09/814,123	
				APPLICANT Hogenkamp et al.			
				FILING DATE March 22, 2001		GROUP 1626	

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
GS	AL2	EP 0 323 841 A3	09/12/1990	Europe			Yes No
GS	AM2	EP 0 488 959 A2	06/03/1992	Europe			Yes No
GS	AN2	EP 0 323 841 B1	08/04/1993	Europe			Yes No
GS	AO2	WO 96/11911	04/25/1996	WIPO			Yes No
GS	AP2	WO 97/07102	02/27/1997	WIPO			Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)			
GS	AR	2	Brown, J.B. and Stammers, D.W., "Yellow color images by silver and dye bleaching," <i>Chem. Abstracts</i> 57:Abstract No. 12673d, The American Chemical Society (1962).
	AS	2	Brown, C.M., et al., "Neuroprotective properties of lifarizine compared with those of other agents in a mouse model of focal cerebral ischaemia," <i>Br. J. Pharmacol.</i> 115:1425-1432, Stockton Press (August 1995).
GS	AT	2	Buchan, A.M., et al., "AMPA Antagonists: Do They Hold More Promise for Clinical Stroke Trials Than NMDA Antagonists," <i>Suppl. J. Stroke</i> 24:148-152, Lippincott Williams and Wilkins (1993).

EXAMINER	<i>Phoumeen</i>	DATE CONSIDERED	3/5/03
----------	-----------------	-----------------	--------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT				ATTY. DOCKET NO. 1861.1270001/JMC/THN		APPLICATION NO. 09/814,123	
				APPLICANT Hogenkamp et al.			
				FILING DATE March 22, 2001		GROUP 1626	

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
*	AL3	JP 11 199566 A	07/27/1999	Japan			Abstract Yes No
GS	AM3	WO 99/62885	12/09/1999	WIPO			Yes No
GS	AN3	WO 00/57877	10/05/2000	WIPO			Yes No
GS	AO3	EP 1 081 146 A1	03/07/2001	Europe			Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)			
GS	AR	3	Catterall, W.A., "Structure and Function of Voltage-Sensitive Ion Channels," <i>Science</i> 242:50-61, American Association for the Advancement of Science (1988).
	AS	3	Catterall, W.A., "Neurotoxins That Act on Voltage-Sensitive Sodium Channels in Excitable Membranes," <i>Ann. Rev. Pharmacol. Toxicol</i> 20:15-43, Annual Reviews Inc. (1980).
GS	AT	3	Catterall, W.A., "Common modes of drug action on Na ⁺ channels: local anesthetics, antiarrhythmics and anticonvulsants," <i>Trends Pharmacol. Sci.</i> 8:57-65, Elsevier Science Publishers B.V. (1987).

EXAMINER	<i>Amphameu</i>	DATE CONSIDERED	3/1/03
----------	-----------------	-----------------	--------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

* Non-english documents

FORM PTO-1449 <u>INFORMATION DISCLOSURE STATEMENT</u>				ATTY. DOCKET NO. 1861.1270001/JMC/THN		APPLICATION NO. 09/814,123	
APPLICANT Hogenkamp et al.				FILING DATE March 22, 2001		GROUP 1626	

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)			
GS	AR	4	Cocco, M.T., et al., "Phytotoxic Activity in Pyrazole Derivatives II," <i>Il Farmaco Ed. Sc.</i> 40:272-284, Società Italiana Di Scienze Farmaceutiche (1985).
	AS	4	Creveling, C.R., et al., "Batrachotoxin-Induced Depolarization and [³ H] Batrachotoxinin-A 20 α -Benzoate Binding in a Vesicular Preparation from Guinea Pig Cerebral Cortex," <i>Mol. Pharmacol.</i> 23:350-358, The American Society for Pharmacology and Experimental Therapeutics (1983).
GS	AT	4	Del Monte, D. and Veggetti, P., "Derivatives of pyrazolone and pyrazolyl carbamates," <i>Chem. Abstracts</i> 53:Abstract No. 8122f, The American Chemical Society (1959).

EXAMINER 	DATE CONSIDERED 3/5/03
--------------	---------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
1861.1270001/JMC/THNAPPLICATION NO.
09/814,123APPLICANT
Hogenkamp et al.FILING DATE
March 22, 2001GROUP
1626

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

GS	AR	5	Denicoff, K.D., et al., "Efficacy of Carbamazepine Compared With Other Agents: A Clinical Practice Survey," J. Clin. Psychiatry 55:70-76, Physicians' Postgraduate Press, Inc. (1994).
↓	AS	5	Dimmock, J.R., et al., "Evaluation of the thiosemicarbazones of some aryl alkyl ketones and related compounds for anticonvulsant activities," Eur. J. Med. Chem. 26:529-534, Elsevier Science (1991).
GS	AT	5	Donaldson, I., "Tegretol: A double blind trial in tinnitus," J. Laryngol. Otol. 95:947-951, Royal Society of Medicine Press (1981).

EXAMINER

Arumman

DATE CONSIDERED

3/5/03

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTD-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
1861.1270001/JMC/THNAPPLICATION NO.
09/814,123APPLICANT
Hogenkamp et al.FILING DATE
March 22, 2001GROUP
1626

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

GS	AR	6	Filer, C.N., "Chapter 6, The Preparation and Characterization of Tritiated Neurochemicals," In: Isotopes in the Physical and Biomedical Sciences, Volume 1, Labelled Compounds (Part A), Buncel, E. and Jones, J.R. eds., pp.156-192, Elsevier Science Publishers B.V. (1987).
↓	AS	6	J.R. Geigy A.-G., "Diazo dyes," Chem. Abstracts 60:Abstract No. 12144b, The American Chemical Society (1964).
GS	AT	6	Graham, S.H., et al., "Neuroprotective Effects of a Use-Dependent Blocker of Voltage-Dependent Sodium Channels, BW619C89, in Rat Middle Cerebral Artery Occlusion," J. Pharmacol. Exp. Ther. 269:854-859, The American Society for Pharmacology and Experimental Therapeutics (1994).

EXAMINER

DATE CONSIDERED

3/5/03

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449

INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.
1861.1270001/JMC/THNAPPLICATION NO.
09/814,123APPLICANT
Hogenkamp et al.FILING DATE
March 22, 2001GROUP
1626

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

GS	AR	Z	Graham, S.H., et al., "A Dose-Response Study of Neuroprotection Using the AMPA Antagonist NBQX in Rat Focal Cerebral Ischemia," J. Pharmacol. Exp. Ther. 276:1-4, The American Society for Pharmacology and Experimental Therapeutics (1996).
↓	AS	Z	Hamill, O.P., et al., "Improved Patch-Clamp Techniques for High-Resolution Current Recording from Cells and Cell-Free Membrane Patches," Pflügers Arch. 391:85-100, Springer-Verlag (1981).
GS	AT	Z	Hunnskaar, S. et al., "Formalin test in mice, a useful technique for evaluating mild analgesics," J. Neurosci. Methods 14:69-76, Elsevier Science Publishers B.V.(1985).

EXAMINER

MA Shamen

DATE CONSIDERED

3/8/02


EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 1861.1270001/JMC/THN	APPLICATION NO. 09/814,123
	APPLICANT Hogenkamp et al.	
	FILING DATE March 22, 2001	GROUP 1626

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)			
GS	AR	8	Iwasaki, Y., et al., "CNQX prevents spinal motor neuron death following sciatic nerve transection in newborn rats," <i>J. Neurosci.</i> 134:21-25, Elsevier Science B.V. (1995).
↓	AS	8	Kuo, C.-C. and Bean, B.P., "Slow Binding of Phenytoin to Inactivated Sodium Channels in Rat Hippocampal Neurons," <i>Mol. Pharmacol.</i> 46:716-725, The American Society for Pharmacology and Experimental Therapeutics (1994).
GS	AT	8	Lam, P.Y.S., et al., "New Aryl/Heteroaryl C-N Bond Cross-coupling Reactions via Arylboronic Acid/Cupric Acetate Arylation," <i>Tetrahedron Lett.</i> 39:2941-2944, Elsevier Science Ltd. (1998).

EXAMINER 	DATE CONSIDERED 3/8/03
---	---------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 1861.1270001/JMC/THN	APPLICATION NO. 09/814,123
	APPLICANT Hogenkamp et al.	
	FILING DATE March 22, 2001	GROUP 1626

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)			
GS	AR	2	Majumdar, B., et al., "An electrocochleographic study of the effects of lignocaine on patients with tinnitus," <i>Clin. Otolaryngol</i> 8:175-180, Blackwell Scientific Publications (1983).
↓	AS	2	Magnoli, R., "1-(p-Benzoylphenyl)-3-alkyl(or benzamido)-5-pyrazolones as color couplers," <i>Chem. Abstracts</i> 65:Abstract No. 5576g, The American Chemical Society (1966).
GS	AT	2	Møller, A.R., "Similarities Between Chronic Pain and Tinnitus," <i>Am. J. Otol.</i> 18:577-585, Lippincott-Raven Publishers (1997).

EXAMINER	<i>Barham</i>	DATE CONSIDERED	3/9/03
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.			

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 1861.1270001/JMC/THN	APPLICATION NO. 09/814,123
	APPLICANT Hogenkamp et al.	
	FILING DATE March 22, 2001	GROUP 1626

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)							
GS	AR	11	Polevoi, L.G., et al., "Relation of aminopyrazole structures to their neurotropic activity," retrieved from STN, Database Accession No. 69:1557 CAPLUS, Chemical Abstracts Service (1968).				
	AS	11	Ragsdale, D.S., et al., "Frequency and Voltage-Dependent Inhibition of Type IIA Na ⁺ Channels, Expressed in a Mammalian Cell Line, by Local Anesthetic, Antiarrhythmic, and Anticonvulsant Drugs," Mol. Pharmacol. 40:756-765, Williams & Wilkins (1991).				
GS	AT	11	Rasavi, D., "Reactive dyes," Chem. Abstracts 59:Abstract 6555g, The American Chemical Society (1963).				

EXAMINER <i>Amthauer</i>	DATE CONSIDERED 3/5/03
-----------------------------	---------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 1861.1270001/JMC/THM	APPLICATION NO. 09/814,123
	APPLICANT Hogenkamp <i>et al.</i>	
	FILING DATE March 22, 2001	GROUP 1626

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)							
GS	AR	12	Sheardown, M.J., <i>et al.</i> , "AMPA, but not NMDA, receptor antagonism is neuroprotective in gerbil global ischaemia, even when delayed 24 h," <i>Eur. J. Pharmacol.</i> 236:347-353, Elsevier Science Publishers B.V. (1993).				
↓	AS	12	Simpson, J.J., and Davies, W.E., "Recent advances in the pharmacological treatment of tinnitus," <i>Trends Pharmacol. Sci.</i> 20:12-18, Elsevier Science London (1999).				
GS	AT	12	Steck, E.A., <i>et al.</i> , "Some Guanazole Derivatives," <i>J. Am. Chem. Soc.</i> 80:3929-3931, The American Chemical Society (1958).				

EXAMINER <i>Amphauer</i>	DATE CONSIDERED 3/5/03
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.	

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 1861.1270001/JMC/THN	APPLICATION NO. 09/814,123
	APPLICANT Hogenkamp et al.	
	FILING DATE March 22, 2001	GROUP 1626

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)							
GS	AR	13	Steck, E.A., and Nachod, F.C., "Absorption Spectra of Heterocyclic Compounds. VII. Some 3(2H)-Pyridazones," J. Am. Chem. Soc. 79:4408-4411, The American Chemical Society (1957).				
	AS	13	Stefancich, G., et al., "Analogues of Bifonazole with Two Imidazole Moieties and Related Azoles," Arch. Pharm. (Weinheim) 323:273-280, VCH Verlagsgesellschaft mbH (1990).				
GS	AT	13	Stys, P.K., et al., "Ionic Mechanisms of Anoxic Injury in Mammalian CNS White Matter: Role of Na ⁺ Channels and Na ⁺ -Ca ²⁺ Exchanger," J. Neurosci. 12:430-439, Society for Neuroscience (1992).				

EXAMINER <i>M. S. Hansen</i>	DATE CONSIDERED 3/5/03
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.	

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 1861.1270001/JMC/THN	APPLICATION NO. 09/814,123
	APPLICANT Hogenkamp et al.	
	FILING DATE March 22, 2001	GROUP 1626

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

GS	AR	16	Taylor, C.P., and Meldrum, B.S., "Na ⁺ channels as targets for neuroprotective drugs," <i>Trends Pharmacol. Sci.</i> 16:309-316, Elsevier Trends Journals (1995).
	AS	16	Tonndorf, J., "The analogy between tinnitus and pain: A suggestion for a physiological basis of chronic tinnitus," <i>Hear Res.</i> 28:271-275, Elsevier Science Publishers B.V. (1987).
GS	AT	16	Verdoorn, T.A., et al., "Functional Properties of Recombinant Rat GABA _A Receptors Depend upon Subunit Composition," <i>Neuron</i> 4:919-928, Cell Press (1990).

EXAMINER	<i>MAHauer</i>	DATE CONSIDERED	3/5/03
----------	----------------	-----------------	--------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449		ATTY. DOCKET NO. 1861.1270001/JMC/THN		APPLICATION NO. 09/814,123	
INFORMATION DISCLOSURE STATEMENT		APPLICANT Hogenkamp et al		FILING DATE March 22, 2001	
		GROUP 1626			
U.S. PATENT DOCUMENTS					
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS
	AA				
	AB				
	AC				
	AD				
	AE				
	AF				
	AG				
	AH				
	AI				
	AJ				
	AK				
FOREIGN PATENT DOCUMENTS					
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS
	AL				
	AM				
	AN				
	AO				
	AP				
OTHER (Including Author, Title, Date, Pertinent Pages, etc.)					
GS	AR	15	Wrathall, J.R., et al., "Amelioration of Functional Deficits from Spinal Cord Trauma with Systemically Administered NBQX, an Antagonist of Non-N-methyl-D-aspartate receptors," <i>Exp. Neurol.</i> 137:119-126, Academic Press, Inc. (1996).		
	AS	15	Zweidler, R. and Keller, E., "Fluorescent ditriazole compounds," <i>Chem. Abstracts</i> 52:Abstract No. 8206c, The American Chemical Society (1958).		
GS	AT	15	Dialog File 351, Accession No. 669110, Derwent WPI English Language abstract for DE 19 36 760 (Document A1).		
EXAMINER				DATE CONSIDERED 3/5/02	
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.					

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 1861.1270001/JMC/THN	APPLICATION NO. 09/814,123
	APPLICANT Hogenkamp et al.	
	FILING DATE March 22, 2001	GROUP 1626

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AN						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)							
GS	AR	16	Dialog File 351, Accession No. 2553655, Derwent WPI English language abstract for DE 29 10 330 A1 (Document AM1).				
	AS	16	Dialog File 351, Accession No. 12667941, Derwent WPI English Language abstract for JP 11 199566 A (Document AL3).				
GS	AT	16	International Search Report for International Application No. PCT/US 01/08972, mailed September 24, 2001.				

EXAMINER <i>MShaheen</i>	DATE CONSIDERED 315703
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.	